CCC Diagnostics Inc Announces Expanded Insurance Coverage for the DirectHit Panel for Breast Cancer
CCC Diagnostics Inc has received expanded insurance coverage for the DirectHit Panel for Breast Cancer. This expanded coverage includes CareFirst BlueCross/Blue Shield, WellPoint Unicare Networks, CMS Highmark Medicare Services and AmeriGroup.
BALTIMORE, MD, February 04, 2011
CCC Diagnostics, Inc (CCCD), announced today that the Centers for Medicare & Medicaid will provide coverage for their Drug Response Indicator Test trademarked as the Breast Cancer DirectHitTM Test Panel for Breast Cancer. In addition to Medicare, CareFirst BlueCross/Blue Shield, WellPoint Unicare Networks, CMS Highmark Medicare Services and AmeriGroup will also provide coverage.The DirectHit Panel analyzes an individual patient's tumor in order to indicate the response to commonly prescribed anti-breast cancer chemotherapy drugs. DirectHit provides information about the tumor that may be used in addition to the usual tests to prescribe the most effective anticancer drug treatment.
John Hughes, CEO of CCC Diagnostics, commented " We are very pleased with the expanded coverage afforded DirectHit by the major health insurance providers. This expanded coverage will allow more patients to have access to DirectHit testing. Which is a significant step forward for physicians and their patients because the treatment will now have a higher probability of affecting the tumor."
"No longer must one breast cancer treatment fit all," says Mr. Hughes, which should be welcome news for
physicians and their patients."
CCC Diagnostics, Inc. actively integrates discoveries in diagnostic, therapeutic and information technologies to create innovative approaches to cancer disease management and to enhance the quality of life for cancer patients. Our strategy is to provide effective, personalized chemotherapy treatment recommendations, increasing life quality and decreasing cost through appropriate drug choice.